{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"63.96","upperLimit":"89.96","value":"79.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"43"}],"units":"Participants"}],"description":"ORR is defined as the percentage of participants with a minor, partial, very good partial, and complete response, as assessed by an independent review committee using modified Owen's criteria","dispersionType":"95% Confidence Interval","groups":[{"description":"Zanubrutinib 160 mg orally twice daily with or without food until progressive disease or intolerable toxicity","id":"OG000","title":"Zanubrutinib"}],"paramType":"NUMBER","populationDescription":"Efficacy Analysis Set includes participants with confirmed Waldenström's macroglobulinemia based on central pathologic review among those who received at least one dose of study drug and with a baseline IgM (or M-protein) ≥ 5 g/L","reportingStatus":"POSTED","timeFrame":"Up to approximately 1 year and 9 months","title":"Overall Response Rate (ORR)","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}